Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25247062 | 0.79 | ALDH1A1 (0.38) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL1908673 | 0.78 | ALDH1A1 (0.41) | PTGS2MCHR1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL8812209 | 0.77 | SCN5A (0.53) | SCN5AALDH1A1HSD17B10 | |
| SCHEMBL2118968 | 0.77 | SCN5A (0.53) | SCN5APTGS2PTGS1MCHR1ALDH1A1 | |
| SCHEMBL12056714 | 0.75 | SCN5A (0.54) | SCN5APTGS2PTGS1MCHR1ALDH1A1 | |
| SCHEMBL516957 | 0.74 | PIK3CG (0.55) | SCN5AMCHR1ALDH1A1 | |
| SCHEMBL18080888 | 0.74 | SCN5A (0.53) | SCN5APTGS2PTGS1MCHR1ALDH1A1 | |
| SCHEMBL4487089 | 0.73 | SCN5A (0.49) | SCN5AMCHR1ALDH1A1 | |
| SCHEMBL16739619 | 0.72 | KDM4E (0.50) | SCN5AMCHR1ALDH1A1 | |
| SCHEMBL15829424 | 0.71 | SCN5A (0.50) | SCN5AMCHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8697739-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| EP-2598486-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | Novartis AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | SCN5A 1988/4885PTGS2 1885/4885PTGS1 1385/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | SCN5A 1988/4885PTGS2 1885/4885PTGS1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.